Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial

被引：0
|
作者：
Kasper, S. [1 ]
van Cutsem, E. [2 ]
Ciardello, F. [3 ]
Ychou, M. [4 ]
Seitz, J. -F [5 ]
Hofheinz, R. -D [6 ]
Arriaga, Y. E. [7 ]
Verma, U. [7 ]
Garcia-Carbonero, R. [8 ]
Grothey, A. [9 ]
Miriyala, A. [10 ]
Kalmus, J. [10 ]
Kappeler, C. [10 ]
Falcone, A. [11 ]
Zaniboni, A. [12 ]
机构：
[1] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Essen, Germany
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Univ Naples 2, Naples, Italy
[4] Inst Reg Canc Montpellier, Montpellier, France
[5] Aix Marseille Univ, Marseille, France
[6] Univ Klin Mannheim, Mannheim, Germany
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] Hosp Univ Doce Octubre, Madrid, Spain
[9] Mayo Clin, Rochester, MN USA
[10] Bayer Pharma AG, Berlin, Germany
[11] Univ Pisa, Pisa, Italy
[12] Fdn Poliambulanza, Brescia, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P304
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [1] Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial
    Ciardiello, F.
    Salvatore, L.
    Cascinu, S.
    Sobrero, A.
    Banzi, C.
    Barone, C.
    Spallanzani, A.
    Latiano, T. P.
    Siena, S.
    Bergamo, F.
    Carteni, G.
    Di Costanzo, F.
    Di Bartolomeo, M.
    Santoro, A.
    Russo, A.
    Russo, A.
    Moscovici, M.
    Van Cutsem, E.
    Grothey, A.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial.
    Van Cutsem, Eric
    Ciardiello, Fortunato
    Ychou, Marc
    Seitz, Jean Francois
    Hofheinz, Ralf
    Arriaga, Yull Edwin
    Verma, Udit
    Garcia-Carbonero, Rocio
    Grothey, Axel
    Miriyala, Ashok
    Kalmus, Joachim
    Kappeler, Christian
    Falcone, Alfredo
    Zaniboni, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Ciardiello, F.
    Ychou, M.
    Seitz, J. -F.
    Hofheinz, R.
    Arriaga, Y.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Kappeler, C.
    Falcone, A.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 106 - 106
  • [4] Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Ciardiello, F.
    Seitz, J. -F.
    Hofheinz, R. D.
    Verma, U.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Shapiro, J.
    Falcone, A.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 42 - 42
  • [5] Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study
    Ciardiello, F.
    Falcone, A.
    Cascinu, S.
    Sobrero, A.
    Boni, C.
    Barone, C.
    Luppi, G.
    Maiello, E.
    Siena, S.
    Zagonel, V.
    Carteni, G.
    Di Constanzo, F.
    Di Bartolomeo, M.
    Santoro, A.
    Russo, A.
    Moscovici, M.
    Van Cutsem, E.
    Zaniboni, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S380 - S381
  • [6] CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
    Van Cutsem, E.
    Ciardiello, F.
    Seitz, J. F.
    Hofheinz, R. D.
    Verma, U.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Shapiro, J.
    Falcone, A.
    Zaniboni, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S378 - S379
  • [7] Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
    Ciardiello, F.
    Salvatore, L.
    Cascinu, S.
    Sobrero, A.
    Banzi, M.
    Barone, C.
    Spallanzani, A.
    Latiano, T. L.
    Amatu, A.
    Zagonel, V.
    Biglietto, M.
    Di Costanzo, F.
    Di Bartolomeo, M.
    Santoro, A.
    Russo, A.
    Moscovici, M.
    Van Cutsem, E.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
  • [8] Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.
    Verma, Udit
    Arriaga, Yull Edwin
    Lenz, Heinz-Josef
    Henderson, Charles A.
    Fuloria, Jyotsna
    Cartwright, Thomas H.
    Khojasteh, Ali
    Stella, Philip J.
    Saltzman, Marc
    Cohn, Allen Lee
    Philip, Philip Agop
    Kappeler, Christian
    Kalmus, Joachim
    Grothey, Axel
    Van Cutsem, Eric
    Hochster, Howard S.
    Arena, Francis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] CONSIGN - an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
    Hofheinz, R. -D
    Glardello, F.
    Seitz, J-F
    Verma, U.
    Garcia-Carbonero, R.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Shapiro, J.
    Falcone, A.
    Zanibonl, A.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 10 - 10
  • [10] Regorafenib in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial
    Vogel, A.
    van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Humblet, Y.
    Buchet, O.
    Mineur, L.
    Barone, C.
    Adenis, A.
    Tabernero, J.
    Yoshino, T.
    Lenz, H-J
    Goldberg, R. M.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ONKOLOGIE, 2013, 36 : 69 - 70
12345